RxDoctor Payments Data

Brandy Gooss

Family · Jal, NMNPI 1841449667

Payments from drug & device makers

$228in general payments, 2019–2025

Across 11 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$42
  • Johnson & Johnson$38
  • Boehringer Ingelheim$27
  • Lilly USA, LLC$23
  • Pfizer$22
  • Xeris Pharmaceuticals, Inc.$20
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$228 in reported general payments places this provider in the 50th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$37,699
Medicare patients
127
Services billed
4,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin88$68,064
MounjaroTirzepatide41$49,782
OzempicSemaglutide23$30,560
EliquisApixaban31$27,795
Teriparatide11$26,786
TrulicityDulaglutide26$25,956
LinzessLinaclotide26$13,763
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$13,758
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,348
JanuviaSitagliptin Phosphate14$11,744
TradjentaLinagliptin19$10,210
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$9,677
FarxigaDapagliflozin Propanediol16$9,133
KerendiaFinerenone11$7,295
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$5,741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$27$83,628119 claims
Lilly USA, LLCMounjaro, Trulicity$23$75,73867 claims
Novo NordiskOzempic$20$30,56023 claims
PfizerEliquis$22$27,79531 claims
AbbVieLinzess, Synthroid$42$14,52338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,080 family providers in New Mexico.

Other family in Jal

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →